D-Sight

D-Sight is a biotechnology company spun off from the Vall d’Hebron Institute of Research (VHIR). The company focuses on discovering and developing innovative treatments for neurodegenerative diseases of the retina. Their primary product under development is a novel, first-in-class eye drop formulation designed to prevent and treat diabetic retinopathy in its early stages, addressing a significant unmet medical need for non-invasive therapies.